joseph c. cook, jr., a 28-year veteran at eli lilly & co. and an amylin board member since 1994, came out of retirement in 1998 to help the company recover its footing, taking the title of chief executive officer. cook reduced the company's workforce by 75 percent to conserve cash and raised capital from investors to keep symlin (pramlintide's commercial name) moving through the regulatory pipeline.